Company intelligence / Profile preview

Clearpath

Rockville, Maryland, USA

Ownership: Private
Development stage: Other

Overview

ClearPath Development Company accelerates the development and de-risking of early-stage vaccine and biologic assets, primarily focusing on unmet medical needs in infectious disease. The company has launched pipeline companies around innovative vaccine technologies such as MAPS, targeting resistant nosocomial pathogens in partnership with Astellas, Affinivax, and academic centers. Lead programs are progressing through preclinical and translational phases but not yet in the clinic as of most recent reporting.

Therapeutic areas: Infectious Diseases
Modalities: VaccineMonoclonal antibodyBiologic
Industry: Biotech

Partnerships

Astellas PharmaAffinivaxUniversity of Maryland School of Medicine

Beyond the preview

Go deeper on Clearpath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clearpath.

Explore the full profile